601607 上海医药
已收盘 04-10 15:00:00
资讯
新帖
简况
上海医药：公司挂牌转让上海施贵宝项目正有序推进中
每日经济新闻 · 04-09 16:15
上海医药：公司挂牌转让上海施贵宝项目正有序推进中
上海医药(601607.SH)：地高辛片通过仿制药一致性评价
智通财经 · 04-08
上海医药(601607.SH)：地高辛片通过仿制药一致性评价
上海医药：下属公司硫酸妥布霉素注射液通过仿制药一致性评价
财中社 · 04-08
上海医药：下属公司硫酸妥布霉素注射液通过仿制药一致性评价
里昂：升上海医药(02607)目标价至15.2港元 评级“跑赢大市”
智通财经 · 04-08
里昂：升上海医药(02607)目标价至15.2港元 评级“跑赢大市”
每周股票复盘：上海医药（601607）2025年归母净利润增25.74%
证券之星 · 04-05
每周股票复盘：上海医药（601607）2025年归母净利润增25.74%
上海医药发布2025年业绩报告，营收2835.52亿元，同比增长3.03%
蓝鲸财经 · 04-01
上海医药发布2025年业绩报告，营收2835.52亿元，同比增长3.03%
瑞银：升上海医药(02607)目标价至15.2港元 评级为“买入”
智通财经 · 04-01
瑞银：升上海医药(02607)目标价至15.2港元 评级为“买入”
上海医药(02607)发布2025年度业绩，归母净利润57.25亿元，同比上升25.74%
智通财经 · 03-30
上海医药(02607)发布2025年度业绩，归母净利润57.25亿元，同比上升25.74%
上海医药2025年度分红预案：拟每10股派发现金红利3.50元
美股速递 · 03-30
上海医药2025年度分红预案：拟每10股派发现金红利3.50元
每周股票复盘：上海医药（601607）二羟丙茶碱注射液获批生产
证券之星 · 03-29
每周股票复盘：上海医药（601607）二羟丙茶碱注射液获批生产
上海医药孙公司被指卷入巨额经济纠纷
中国经营网 · 03-28
上海医药孙公司被指卷入巨额经济纠纷
上海医药：二羟丙茶碱注射液获批生产
人民财讯 · 03-26
上海医药：二羟丙茶碱注射液获批生产
上海医药：公司控股股东已发布增持计划（请见临时公告2025-083）
证券日报 · 03-24
上海医药：公司控股股东已发布增持计划（请见临时公告2025-083）
每周股票复盘：上海医药（601607）注射用头孢唑林钠通过一致性评价
证券之星 · 03-22
每周股票复盘：上海医药（601607）注射用头孢唑林钠通过一致性评价
上海医药(601607.SH)：注射用头孢唑林钠通过一致性评价
智通财经 · 03-17
上海医药(601607.SH)：注射用头孢唑林钠通过一致性评价
上海医药：2025年公司与多家药企达成战略合作
证券日报 · 03-02
上海医药：2025年公司与多家药企达成战略合作
每周股票复盘：上海医药（601607）利伐沙班片获新加坡注册证
证券之星 · 03-01
每周股票复盘：上海医药（601607）利伐沙班片获新加坡注册证
上海医药(02607)：普瑞巴林胶囊获得菲律宾药品注册证书
智通财经 · 02-27
上海医药(02607)：普瑞巴林胶囊获得菲律宾药品注册证书
上海医药(601607.SH)：利伐沙班片获得新加坡药品注册证书
智通财经 · 02-24
上海医药(601607.SH)：利伐沙班片获得新加坡药品注册证书
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
21世纪经济报道 · 02-12
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":17.16,"timestamp":1775804400000,"preClose":17.09,"halted":0,"volume":10479633,"delay":0,"changeRate":0.0041,"floatShares":2789000000,"shares":3708000000,"eps":1.8598,"marketStatus":"已收盘","change":0.07,"latestTime":"04-10 15:00:00","open":17.15,"high":17.25,"low":17.03,"amount":180000000,"amplitude":0.0129,"askPrice":17.16,"askSize":176,"bidPrice":17.15,"bidSize":140,"shortable":0,"etf":0,"ttmEps":1.8598,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":17.09,"symbolType":"stock","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":18.8,"lowLimit":15.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.84,"roa":"--","peRate":9.226799,"roe":"7.74%","epsLYR":1.54,"committee":0.100079,"marketValue":63635000000,"turnoverRate":0.0038,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-13。","hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.99,"timestamp":1775808560007,"preClose":11.96,"halted":0,"volume":1612696,"delay":0,"premium":"-39.04"},"floatMarketCap":47863000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2626902114","title":"上海医药：公司挂牌转让上海施贵宝项目正有序推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902114","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902114?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:15","pubTimestamp":1775722547,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问公司挂牌转让所持上海施贵宝股份进展如何？公司今年对创新药研发计划投入由增加吗？上海医药（601607.SH）4月9日在投资者互动平台表示，公司挂牌转让上海施贵宝项目正有序推进中，相关交易进展公司会按照监管要求及时履行信息披露义务，请您继续关注公司公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699584342.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699584342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0321505868.SGD","LU1868836757.USD","LU1261432733.SGD","LU0882574055.USD","02607","LU1032466523.USD","LU0096364046.USD","BK0188","BK0020","LU1074936037.SGD","BK0183","LU2242652126.USD","LU0237698245.USD","LU1868836914.USD","601607","BK4559","LU1585245621.USD","LU0306807586.USD","LU2242646821.SGD","BK0184","LU1670711040.USD","BK1197","LU2133065610.SGD","BK4588","LU1291159041.SGD","BMY","BK0012","LU1868837136.USD","LU2360032135.SGD","LU1323610961.USD","BK0187","LU1868837300.USD","LU1883839398.USD","BK4532","LU2125154935.USD","BK0028","BK4585","BK0209","LU0985481810.HKD","LU0114720955.EUR","LU0225771236.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0321505439.SGD","LU1093756325.SGD","LU1670711123.USD","IE00BFTCPJ56.SGD","LU0267386448.USD","BK4534","LU0061475181.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625916959","title":"上海医药(601607.SH)：地高辛片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2625916959","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625916959?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:04","pubTimestamp":1775635449,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司下属上海上药信谊药厂有限公司的地高辛片收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。地高辛片适用于1、治疗成人轻度至中度心力衰竭。地高辛可增加左心室射血分数并改善心力衰竭症状，表现为提高运动能力和减少心力衰竭相关住院和急诊治疗，而对死亡率无影响。在可能的情况下，地高辛应与利尿剂和血管紧张素转换酶抑制剂联合使用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0187","BK0183","BK0012","601607","BK0020","BK0097","BK0196","BK0188","BK0099","BK0184","BK0209","BK0028","BK1197","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625916857","title":"上海医药：下属公司硫酸妥布霉素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2625916857","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625916857?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:50","pubTimestamp":1775634600,"startTime":"0","endTime":"0","summary":"4月8日，上海医药（601607/02607）发布公告，近日，公司下属上药禾丰的硫酸妥布霉素注射液收到国家药监局颁发的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。该药品的规格为2ml：80mg，适用于多种感染症状。2025年1月，上药禾丰向国家药监局提出了该药品的一致性评价补充申请，并获得受理，相关研发费用约为438万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698020185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","02607","BK0183","BK0188","BK1197","BK0012","BK0028","BK0184","BK0020","BK0187","601607","BK0097","BK0099","BK0175","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625991306","title":"里昂：升上海医药(02607)目标价至15.2港元 评级“跑赢大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2625991306","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625991306?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:28","pubTimestamp":1775633337,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，上海医药(02607) 2025财年收入2,836亿元人民币，同比增加3%，净利润57.3亿元人民币，同比增加25.7%，均与市场预期基本一致。中药一直是公司生产业务的核心驱动力，公司将继续优先发展创新药物研发以推动增长。该行将其目标价由14.2港元上调至15.2港元，维持“跑赢大市”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625061631","title":"每周股票复盘：上海医药（601607）2025年归母净利润增25.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625061631","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625061631?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:52","pubTimestamp":1775325130,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，上海医药报收于17.31元，较上周的16.69元上涨3.71%。本周，上海医药4月2日盘中最高价报17.37元。3月30日盘中最低价报16.54元。上海医药当前最新总市值641.92亿元，在医药商业板块市值排名1/32，在两市A股市值排名286/5193。2025年第四季度，公司单季度主营收入685.07亿元，同比上升4.4%；单季度归母净利润5.77亿元，同比上升15.88%；单季度扣非净利润2.82亿元，同比下降25.65%。负债率61.49%，投资收益31.7亿元，财务费用14.07亿元，毛利率10.73%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624466592","title":"上海医药发布2025年业绩报告，营收2835.52亿元，同比增长3.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624466592","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624466592?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:35","pubTimestamp":1775039711,"startTime":"0","endTime":"0","summary":"财报显示，公司实现营业收入2835.52亿元，同比增长3.03%；归母净利润57.25亿元，同比增长25.74%。扣非归母净利润为29.80亿元，同比下降26.68%；若进一步剔除非经常性损益影响，扣非后归母净利润为47.21亿元，同比下降5.56%。销售费用达132.06亿元，同比增长3.87%。经营活动现金流净额为61.54亿元，同比增长5.61%。分红方面，公司2025年度拟派发现金红利12.98亿元，叠加半年度已派发的4.45亿元，累计派现17.43亿元，占归母净利润的30.45%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775036336712856794","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624532596","title":"瑞银：升上海医药(02607)目标价至15.2港元 评级为“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2624532596","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624532596?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:38","pubTimestamp":1775032694,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，上海医药(02607)去年总收入同比升3%至2,840亿元人民币，纯利同比升25.7%至57.2亿元，经常性纯利同比跌26.7%至29.8亿元人民币，大致上符合预期。将上海医药2026至2028年盈利预测下调1%至上调3%，目标价由15港元上调至15.2港元，评级“买入”。该行指出，考虑到上海医药的定位策略、多元化业务以及在快速增长业务中的竞争优势，该行预计上海医药在“十五五”期间的增长将超越其医药分销同行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","02607","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623634353","title":"上海医药(02607)发布2025年度业绩，归母净利润57.25亿元，同比上升25.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623634353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623634353?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:12","pubTimestamp":1774876356,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布2025年度业绩，营业收入2835.80亿元，同比增长3.03%。其中：医药工业实现销售收入245.22亿元，同比增长3.33%;医药商业实现销售收入2590.58亿元，同比增长3.00%。归属于上市公司股东的净利润57.25亿元，同比上升25.74%。归属于上市公司股东的净利润同比上升，主要是由于对和黄药业会计核算由合营企业权益法核算变更为子公司核算所产生的一次性特殊收益所致，扣除上述事项等一次性特殊损益后的归母净利润为47.21亿元，同比下降5.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137199609","title":"上海医药2025年度分红预案：拟每10股派发现金红利3.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137199609","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137199609?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:46","pubTimestamp":1774874806,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司（以下简称“上海医药”）近日披露2025年度利润分配预案，公司计划向全体股东每10股派发现金红利3.50元（含税）。该分红方案体现了公司稳健的盈利能力和回报股东的诚意，若顺利实施，将进一步提升股东权益价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0020","BK0099","BK0175","BK0097","BK0184","BK0012","BK0187","BK0209","BK0028","BK0196","BK0183","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623540338","title":"每周股票复盘：上海医药（601607）二羟丙茶碱注射液获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2623540338","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623540338?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:10","pubTimestamp":1774725024,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，上海医药报收于16.69元，较上周的16.89元下跌1.18%。本周，上海医药3月23日盘中最高价报16.79元。来自公司公告汇总：上海医药将于2026年4月8日召开2025年年度业绩说明会。公司公告汇总上海医药集团股份有限公司下属上海禾丰制药有限公司的二羟丙茶碱注射液获得国家药品监督管理局批准生产，药品注册证书编号为2026S00781，注册分类为化学药品3类。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","BK0175","BK0097","BK0188","BK0028","BK0196","BK0209","02607","BK0020","BK0183","BK0012","BK1197","BK0187","BK0184","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808918","title":"上海医药孙公司被指卷入巨额经济纠纷","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808918","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622808918?lang=zh_cn&edition=full","pubTime":"2026-03-28 04:07","pubTimestamp":1774642068,"startTime":"0","endTime":"0","summary":"总经理下落不明、涉嫌伪造印章、20多家公司牵连……近日，全国第二大医药商业企业上海医药（601607.SH，02607.HK）控股孙公司及其总经理被指卷入巨额经济纠纷。“我的核心诉求是：第一，希望能把240万元中药材款项追回来；第二，上海医药作为国企上市公司，需要对此事公开并妥善处理，需要有人负监管职责；第三，希望此事引起上级纪委监委和国资委的重视。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603283687556246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0209","BK0196","BK0028","BK0183","BK0187","601607","BK0099","BK0184","BK1197","BK0020","BK0188","BK0175","BK0012","BK0097","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622834191","title":"上海医药：二羟丙茶碱注射液获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2622834191","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622834191?lang=zh_cn&edition=full","pubTime":"2026-03-26 15:40","pubTimestamp":1774510800,"startTime":"0","endTime":"0","summary":"人民财讯3月26日电，上海医药(601607)3月26日公告，近日，公司下属上海禾丰制药有限公司的二羟丙茶碱注射液收到国家药监局颁发的《药品注册证书》，该药品获得批准生产。二羟丙茶碱注射液适用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓解喘息症状。也可用于因心源性肺水肿而致的喘息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685478559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK1197","BK0028","BK0012","BK0097","BK0187","BK0099","BK0183","BK0188","BK0209","BK0020","601607","BK0175","BK0196","BK0184"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621619870","title":"上海医药：公司控股股东已发布增持计划（请见临时公告2025-083）","url":"https://stock-news.laohu8.com/highlight/detail?id=2621619870","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621619870?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:29","pubTimestamp":1774351740,"startTime":"0","endTime":"0","summary":"证券日报网讯3月24日，上海医药在互动平台回答投资者提问时表示，公司始终将市值管理作为长期战略的重要组成部分，多措并举加强市场沟通，注重股东回报。一方面，公司将深耕主业发展，以经营业绩的稳健增长来夯实价值根基，提升内在价值，另一方面，公司也积极寻求多元化、可适用的市值管理工具，传递信心、共享成果。截至目前，公司控股股东已发布增持计划（请见临时公告2025-083）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682748841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","BK0012","BK0099","02607","BK0175","BK0209","BK1197","BK0097","BK0183","BK0184","BK0028","BK0196","BK0188","BK0020","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621111799","title":"每周股票复盘：上海医药（601607）注射用头孢唑林钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2621111799","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621111799?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:02","pubTimestamp":1774119738,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，上海医药报收于16.89元，较上周的17.29元下跌2.31%。本周，上海医药3月17日盘中最高价报17.39元。上海医药当前最新总市值626.34亿元，在医药商业板块市值排名1/32，在两市A股市值排名304/5190。该药品适用于治疗敏感细菌所致的多种感染。截至公告日，公司针对该药品的一致性评价已投入研发费用约332.41万元。2025年中国大陆医院采购该药品金额为110,758万元。通过一致性评价有利于提升市场竞争力，扩大市场份额，但存在销售不达预期的风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","BK1197","BK0209","BK0188","BK0184","BK0187","BK0020","BK0183","601607","BK0196","BK0012","BK0028","02607","BK0097","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620441803","title":"上海医药(601607.SH)：注射用头孢唑林钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2620441803","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620441803?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:37","pubTimestamp":1773733056,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)公告，公司下属上海上药新亚药业有限公司(简称“上药新亚”)的注射用头孢唑林钠收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。注射用头孢唑林钠适用于治疗敏感细菌所致的呼吸道感染、尿路感染、皮肤和软组织感染、骨和关节感染、败血症、感染性心内膜炎、肝胆系统感染、生殖系统感染和围手术期预防感染。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","02607","601607","BK0012","BK0099","BK0020","BK0209","BK0184","BK0187","BK0183","BK1197","BK0097","BK0188","BK0028","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616334712","title":"上海医药：2025年公司与多家药企达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334712","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616334712?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:35","pubTimestamp":1772454923,"startTime":"0","endTime":"0","summary":"证券日报网3月2日讯，上海医药在接受调研者提问时表示，公司早年依托既有渠道网络优势，提前布局为制药企业提供合规的合约销售服务，帮助制药企业以更具成本效益的方式拓展市场，加速市场覆盖。凭借严谨合规的管理体系和专业的业务能力，公司已形成品牌美誉度。2025年，公司与多家药企达成战略合作，实现了服务规模与服务能级的双提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603023658779879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0099","BK0175","BK0097","BK0188","BK0028","BK0196","BK0209","02607","BK0020","BK0183","BK0012","BK1197","BK0187","BK0184","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616454408","title":"每周股票复盘：上海医药（601607）利伐沙班片获新加坡注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616454408","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616454408?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:59","pubTimestamp":1772305147,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，上海医药报收于17.2元，较上周的17.16元上涨0.23%。本周，上海医药2月25日盘中最高价报17.34元。公司公告汇总上海医药集团股份有限公司下属常州制药厂有限公司生产的利伐沙班片获得新加坡食品药品监督管理局颁发的药品注册证书，具备在新加坡上市销售资格。此前该药品已获美国FDA批准及马来西亚注册证书。截至公告日，公司在东南亚市场相关研发费用约219万元。目前菲律宾有19家销售商，2024年该药品市场销售额为1,337万美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0020","BK0183","BK0012","601607","BK0188","BK0209","BK0097","BK0187","BK0175","BK0099","BK0184","BK1197","02607","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614838513","title":"上海医药(02607)：普瑞巴林胶囊获得菲律宾药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614838513","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614838513?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:39","pubTimestamp":1772181596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，近日，公司下属常州制药厂有限公司生产的普瑞巴林胶囊收到菲律宾食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。普瑞巴林胶囊主要用于治疗带状疱疹后神经痛、糖尿病外周神经痛、纤维肌痛和脊髓损伤引起的神经性疼痛以及癫痫的辅助治疗。 本次普瑞巴林胶囊3个规格(50mg、75mg、150mg)获得菲律宾食品药品监督管理局的药品注册批文，标志着公司具备了在菲律宾市场销售该药品的资格，对公司拓展海外市场带来积极影响，并积累了宝贵的经验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0175","BK0209","BK0097","BK1197","BK0183","BK0099","BK0187","BK0196","BK0184","BK0188","BK0028","601607","BK0012","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613798673","title":"上海医药(601607.SH)：利伐沙班片获得新加坡药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2613798673","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613798673?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:44","pubTimestamp":1771919082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(以下简称“常州制药厂”)生产的利伐沙班片(以下简称“该药品”)收到新加坡食品药品监督管理局(HSA)颁发的药品注册证书，该药品获得批准上市。本次利伐沙班片3个规格(10mg、15mg、20mg)获得新加坡食品药品监督管理局的药品注册批文，标志着该药品已具备在新加坡上市销售的资格，对公司拓展海外市场带来积极影响，并积累宝贵的经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0184","BK0175","BK0188","02607","BK0099","BK0183","BK0020","BK0187","BK0209","BK0012","BK0196","BK1197","BK0097","BK0028","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610960339","title":"新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960339","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960339?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:27","pubTimestamp":1770852424,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委等11部门联合印发《国家基本药物目录管理办法》2月11日，国家卫生健康委等联合印发《国家基本药物目录管理办法》。与原有的文件相比，《国家基本药物目录管理办法》主要修订六个方面：一是增加法律政策依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123648366353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123648366353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","LU1781817850.SGD","BK0099","BK0196","LU1146622755.USD","LU1064131003.USD","LU2097828631.EUR","LU2289578879.USD","LU1064130708.USD","BK0187","600276","LU1820825898.SGD","BK0239","300142","300683","LU2580892789.USD","LU1328615791.USD","BK0046","BK0183","LU1997245094.SGD","LU2097828557.USD","LU2097828805.USD","LU1997244956.HKD","BK0209","LU2097828474.EUR","LU2148510915.USD","BK0012","LU1997245177.USD","LU2097828714.EUR","BK0060","LU0405327494.USD","LU2328871848.SGD","LU1580142542.USD","LU1969619763.USD","301075","BK0188","LU1655091616.SGD","BK0077","BK0184","LU1255011170.USD","LU2495084118.USD","601607","BK0070","LU2488822045.USD","LU0405327148.USD","BK0097","BK0028","LU2580892862.HKD","BK0020"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775955817613,"stockEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0023},{"period":"3month","weight":-0.0403},{"period":"6month","weight":-0.0595},{"period":"1year","weight":-0.0619},{"period":"ytd","weight":-0.0326}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}